Primrose Bio is heading to AMM Ascent 2026, October 28-30 at the Coronado Island Marriott Resort and Spa, Coronado, CA.

Patrik Engström, PhD, Principal Scientist, will be presenting a scientific poster on Engineered RNA Polymerases for Improved Yield, Integrity, Capping, and dsRNA Control in IVT. Andrew Burch, Chief Executive Officer, and Jennifer Wittbold, Associate Director, Product & BD, will also be in attendance. Come find us and learn more about how Prima RNApols® are advancing mRNA manufacturing.

Engineered RNA Polymerases for Improved Yield, Integrity, Capping, and dsRNA Control in IVT

In vitro transcription, RNA polymerases, capping efficiency, double-stranded RNA, translatability, evolution platform, ultra-high-throughput screening, mRNA manufacturing.

RNA therapeutics are rapidly expanding across a wide range of applications, including oncology, infectious diseases, rare diseases, cardiovascular disease, and autoimmune diseases. Central to RNA manufacturing is in vitro transcription (IVT), a method that uses RNA polymerases to synthesize RNA. To reduce manufacturing costs and unwanted immunostimulatory products, Primrose Bio developed Prima RNApols®, a portfolio of engineered RNA polymerases. These RNA polymerases are designed to integrate into industry mRNA workflows by consistently delivering on key performance indicators: yield, integrity, capping efficiency, and ultra-low double-stranded RNA (dsRNA), increasing translation in human cells.

To develop the high-performance Prima RNApols®, Primrose Bio built an enzyme evolution platform based on ultra-high-throughput screens and protein-engineering approaches. The wealth of data generated by the evolution platform puts Primrose Bio in a favorable position to address future manufacturing challenges through AI-based protein engineering and tailored enzyme evolution.

Primrose Bio’s Prima RNApols® are advancing mRNA manufacturing, offering a stronger alternative to legacy enzymes, improving the scalability, quality, and customization of mRNA therapeutics for the future of medicine.